PT3515924T - Formas cristalinas - Google Patents

Formas cristalinas

Info

Publication number
PT3515924T
PT3515924T PT177714367T PT17771436T PT3515924T PT 3515924 T PT3515924 T PT 3515924T PT 177714367 T PT177714367 T PT 177714367T PT 17771436 T PT17771436 T PT 17771436T PT 3515924 T PT3515924 T PT 3515924T
Authority
PT
Portugal
Prior art keywords
crystalline forms
crystalline
forms
Prior art date
Application number
PT177714367T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of PT3515924T publication Critical patent/PT3515924T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PT177714367T 2016-09-22 2017-09-21 Formas cristalinas PT3515924T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP2016072562 2016-09-22

Publications (1)

Publication Number Publication Date
PT3515924T true PT3515924T (pt) 2022-03-11

Family

ID=59923448

Family Applications (1)

Application Number Title Priority Date Filing Date
PT177714367T PT3515924T (pt) 2016-09-22 2017-09-21 Formas cristalinas

Country Status (27)

Country Link
US (4) US10730896B2 (https=)
EP (2) EP3981774A1 (https=)
JP (1) JP7097369B2 (https=)
KR (1) KR102552795B1 (https=)
CN (1) CN109715639B (https=)
AU (1) AU2017331930B2 (https=)
CA (1) CA3037794A1 (https=)
CL (1) CL2019000728A1 (https=)
CY (1) CY1125052T1 (https=)
DK (1) DK3515924T3 (https=)
EA (1) EA201990723A1 (https=)
ES (1) ES2908572T3 (https=)
HR (1) HRP20220234T1 (https=)
HU (1) HUE057772T2 (https=)
IL (1) IL265445B2 (https=)
LT (1) LT3515924T (https=)
MA (1) MA46266B1 (https=)
MX (1) MX381590B (https=)
MY (1) MY193080A (https=)
PH (1) PH12019500567B1 (https=)
PL (1) PL3515924T3 (https=)
PT (1) PT3515924T (https=)
RS (1) RS62946B1 (https=)
SI (1) SI3515924T1 (https=)
TW (1) TWI752086B (https=)
UA (1) UA124073C2 (https=)
WO (1) WO2018055016A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE057772T2 (hu) 2016-09-22 2022-06-28 Idorsia Pharmaceuticals Ltd Kristályos formák
US11179390B2 (en) 2017-03-15 2021-11-23 Idorsia Pharmaceuticals Ltd Subcutaneous administration of a P2Y12 receptor antagonist
PT4181872T (pt) 2020-07-15 2026-01-22 Viatris Asia Pacific Pte Ltd Composição farmacêutica aquosa compreendendo um antagonista do recetor p2y12
JP2024524658A (ja) * 2021-07-13 2024-07-05 イドルシア・ファーマシューティカルズ・リミテッド 4-((r)-2-{[6-((s)-3-メトキシ-ピロリジン-1-イル)-2-フェニル-ピリミジン-4-カルボニル]-アミノ}-3-ホスホノ-プロピオニル)-ピペラジン-1-カルボン酸ブチルエステルの合成方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5373586A (en) 1976-12-09 1978-06-30 Mitsubishi Chem Ind Ltd New penicillin derivatives
CA2020437A1 (en) 1989-07-05 1991-01-06 Yoshihide Fuse Cinnamamide derivative
DE60022508T2 (de) 1999-06-14 2006-06-08 Eli Lilly And Co., Indianapolis Inhibitoren von serin proteasen
US6861424B2 (en) 2001-06-06 2005-03-01 Schering Aktiengesellschaft Platelet adenosine diphosphate receptor antagonists
OA12970A (en) 2002-12-11 2006-10-13 Schering Ag 2-aminocarbonyl-quinoline compounds as platelet adenosine diphosphate receptor antagonists.
CA2521313A1 (en) 2003-04-09 2004-10-28 Wyeth Derivatives of 2-(8,9-dioxo-2,6-diazabicyclo(5.2.o)non-1(7)-3n-2-yl)-al kyl phosphonic acid and their use as n-methyl-d-aspartate (nmda) recetor antagonists
TW200640877A (en) 2005-04-28 2006-12-01 Actelion Pharmaceuticals Ltd Pyrimidine derivatives
WO2007046075A1 (en) 2005-10-21 2007-04-26 Actelion Pharmaceuticals Ltd Piperazine derivatives as antimalarial agents
AR063258A1 (es) 2006-10-13 2009-01-14 Actelion Pharmaceuticals Ltd Derivados de 2-aminocarbonil-piridina, una composicion farmaceutica que los contiene y su uso en la preparacion de un medicamento para el tratamiento de trastornos vasculares oclusivos.
AR063518A1 (es) 2006-10-25 2009-01-28 Actelion Pharmaceuticals Ltd Derivados 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y su uso para tratar y/o prevenir enfermedades vasculares perifericas viscerales, hepaticas y renales, enfermedades cardiovasculares y enfermedades cerebrovasculares asociados con la agregacion de plaquetas, incluyendo trombosis
JP4785881B2 (ja) 2007-02-27 2011-10-05 大塚製薬株式会社 医薬
KR20100015886A (ko) 2007-04-23 2010-02-12 사노피-아벤티스 P2y12 길항제로서의 퀴놀린-카복스아미드 유도체
ES2388958T3 (es) 2007-11-29 2012-10-22 Actelion Pharmaceuticals Ltd. Derivados de acido fosfonico y su uso como antagonista del receptor P2Y12
EP2238128B1 (en) 2007-12-26 2012-08-22 Sanofi Heterocyclic pyrazole-carboxamides as p2y12 antagonists
WO2009080227A2 (en) 2007-12-26 2009-07-02 Sanofi-Aventis Pyrazole-carboxamide derivatives as p2y12 antagonists
AR071653A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2-fenil-4-ciclopropil-pirimidina
AR071652A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2- fenil-piridina substituidos
KR101694563B1 (ko) 2009-04-08 2017-01-09 액테리온 파마슈티칼 리미티드 Adp 수용체 길항제로서 6-(3-아자-비시클로〔3.1.0〕헥스-3-일)-2-페닐-피리미딘
EP2421859B1 (en) 2009-04-22 2014-04-09 Actelion Pharmaceuticals Ltd. Thiazole derivatives and their use as p2y12 receptor antagonists
HUE057772T2 (hu) 2016-09-22 2022-06-28 Idorsia Pharmaceuticals Ltd Kristályos formák
US11179390B2 (en) 2017-03-15 2021-11-23 Idorsia Pharmaceuticals Ltd Subcutaneous administration of a P2Y12 receptor antagonist
PT4181872T (pt) 2020-07-15 2026-01-22 Viatris Asia Pacific Pte Ltd Composição farmacêutica aquosa compreendendo um antagonista do recetor p2y12

Also Published As

Publication number Publication date
IL265445B1 (en) 2024-01-01
IL265445B2 (en) 2024-05-01
US12227532B2 (en) 2025-02-18
US11365209B2 (en) 2022-06-21
TWI752086B (zh) 2022-01-11
EP3981774A1 (en) 2022-04-13
EP3515924A1 (en) 2019-07-31
US10730896B2 (en) 2020-08-04
TW201813965A (zh) 2018-04-16
KR20190052704A (ko) 2019-05-16
MY193080A (en) 2022-09-26
HRP20220234T1 (hr) 2022-05-13
EA201990723A1 (ru) 2019-10-31
LT3515924T (lt) 2022-03-10
CY1125052T1 (el) 2024-02-16
JP2019529553A (ja) 2019-10-17
NZ750772A (en) 2023-10-27
CN109715639A (zh) 2019-05-03
IL265445A (en) 2019-05-30
MX381590B (es) 2025-03-12
US20220275011A1 (en) 2022-09-01
KR102552795B1 (ko) 2023-07-06
MA46266A (fr) 2019-07-31
MA46266B1 (fr) 2022-02-28
UA124073C2 (uk) 2021-07-14
US20200017534A1 (en) 2020-01-16
PH12019500567A1 (en) 2019-11-18
CL2019000728A1 (es) 2019-07-05
AU2017331930A1 (en) 2019-03-07
ES2908572T3 (es) 2022-05-03
CA3037794A1 (en) 2018-03-29
US20210009614A1 (en) 2021-01-14
EP3515924B1 (en) 2021-12-15
HUE057772T2 (hu) 2022-06-28
US20250163086A1 (en) 2025-05-22
BR112019004845A2 (pt) 2019-06-04
PL3515924T3 (pl) 2022-04-11
JP7097369B2 (ja) 2022-07-07
PH12019500567B1 (en) 2024-01-31
CN109715639B (zh) 2022-04-19
RS62946B1 (sr) 2022-03-31
AU2017331930B2 (en) 2021-07-15
SI3515924T1 (sl) 2022-04-29
DK3515924T3 (da) 2022-03-21
WO2018055016A1 (en) 2018-03-29
MX2019003093A (es) 2019-07-18

Similar Documents

Publication Publication Date Title
IL273730A (en) crystalline forms
AU201616678S (en) Cylindres
PL3445380T6 (pl) Bakterioterapia
DK3270751T3 (en) Foodprocessor
SG10201911417PA (en) Crystalline compounds
SI3380554T2 (sl) Kristalne oblike per-kloro-gama-ciklodekstrinov
IL262674A (en) crystals
GB201614939D0 (en) Crystalline hydrate
SG10202101979TA (en) Crystalline forms of c21h22ci2n4o2
HUE066360T2 (hu) Eravaciklin kristályformái
GB201419174D0 (en) Crystalline forms
IL265445A (en) crystalline forms
IL253479A0 (en) Crystalline forms of efinconazole
PT3390358T (pt) Bis-cloridrato de eravaciclina cristalino
PL3350179T3 (pl) Krystaliczne postacie
GB201604867D0 (en) Rakoom
ZA201902553B (en) Crystalline forms
IL261795A (en) Crystalline form
GB201715010D0 (en) Crystalline forms
GB201708856D0 (en) Seletalisib crystalline forms
HK40009744A (en) Crystalline forms
GB201604759D0 (en) Crystalline compounds
GB201704789D0 (en) Crystalline compounds
AU201616673S (en) tallboy
GB201619882D0 (en) Paint-easy